共 50 条
Malignant pleural effusion: from bench to bedside
被引:187
|作者:
Psallidas, Ioannis
[1
]
Kalomenidis, Ioannis
[2
]
Porcel, Jose M.
[3
]
Robinson, Bruce W.
[4
,5
]
Stathopoulos, Georgios T.
[6
,7
,8
,9
]
机构:
[1] Oxford Univ Hosp Trust, Oxford Ctr Resp Med, Oxford Resp Trials Unit, Oxford, England
[2] Univ Athens, Sch Med, Evangelismos Hosp, Dept Crit Care & Pulm Med 1, Athens, Greece
[3] Arnau de Vilanova Univ Hosp, Biomed Res Inst Lleida, Dept Internal Med, Pleural Med Unit, Lleida, Spain
[4] Univ Western Australia, Sch Med & Pharmacol, Natl Ctr Asbestos Related Dis, Perth, WA, Australia
[5] Sir Charles Gairdner Hosp, Dept Resp Med, Nedlands, WA, Australia
[6] Univ Patras, Fac Med, Dept Physiol, Lab Mol Resp Carcinogenesis, Achaia, Greece
[7] Ludwig Maximilians Univ Munchen, Univ Hosp, Comprehens Pneumol Ctr CPC, Munich, Germany
[8] Helmholtz Zentrum Munchen, Munich, Germany
[9] German Ctr Lung Res DZL, Munich, Germany
基金:
欧洲研究理事会;
关键词:
MESOTHELIAL CELLS;
T-CELLS;
DIFFERENTIAL-DIAGNOSIS;
LUNG ADENOCARCINOMA;
CYTOTOXIC ACTIVITY;
TALC PLEURODESIS;
MOUSE MODEL;
CHEST TUBE;
EFFICACY;
SURVIVAL;
D O I:
10.1183/16000617.0019-2016
中图分类号:
R56 [呼吸系及胸部疾病];
学科分类号:
摘要:
Malignant pleural effusion (MPE) is a common but serious condition that is related with poor quality of life, morbidity and mortality. Its incidence and associated healthcare costs are rising and its management remains palliative, with median survival ranging from 3 to 12 months. During the last decade there has been significant progress in unravelling the pathophysiology of MPE, as well as its diagnostics, imaging, and management. Nowadays, formerly bed-ridden patients are genotyped, phenotyped, and treated on an ambulatory basis. This article attempts to provide a comprehensive overview of current advances in MPE from bench to bedside. In addition, it highlights unanswered questions in current clinical practice and suggests future directions for basic and clinical research in the field.
引用
收藏
页码:189 / 198
页数:10
相关论文